Table 2 Univariate and multivariate analyses for objective response rates (ORR)
From: Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
OR (95%CI) | P value | OR (95%CI) | P value | |
Age, years | Â | 0.405 | Â | Â |
  ≤ 50 | 1.0 |  |  |  |
 >50 | 1.26 (0.73–2.16) |  |  |  |
Gender | Â | 0.128 | Â | Â |
 Female | 1.0 |  |  |  |
 Male | 2.0 (0.82–4.85) |  |  |  |
Vascular invasion | Â | 0.138 | Â | Â |
 No | 1.0 |  |  |  |
 Yes | 1.51 (0.88–2.59) |  |  |  |
Extrahepatic metastasis | Â | 0.002 | Â | 0.112 |
 No | 1.0 |  | 1.0 |  |
 Yes | 0.38 (0.21–0.69) |  | 0.58 (0.30–1.14) |  |
ALBI grade | Â | 0.038 | Â | 0.025 |
 I | 1.0 |  | 1.0 |  |
 II | 0.55 (0.31–0.97) |  | 0.49 (0.26–0.91) |  |
AFP reduction> 50% |  | <0.001 |  | < 0.001 |
 No | 1.0 |  | 1.0 |  |
 Yes | 5.15 (2.85–9.29) |  | 3.36 (1.75–6.45) |  |
PIVKA-II reduction> 50% |  | <0.001 |  | 0.003 |
 No | 1.0 |  | 1.0 |  |
 Yes | 4.43 (2.44–8.05) |  | 2.72 (1.41–5.26) |  |
Baseline AFP level > 400 ng/ml |  | 0.131 |  |  |
 No | 1.0 |  |  |  |
 Yes | 1.58 (0.87–2.84) |  |  |  |
Baseline PIVKA-II level > 400 mAU/ml |  | 0.354 |  |  |
 No | 1.0 |  |  |  |
 Yes | 0.73 (0.37–1.43) |  |  |  |